Brise Pharma Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Series B
- (Cancelled)
- Investors
-
9
Brise Pharma General Information
Description
Developer of new biopharmaceutical drugs intended for treating pain. The company focuses on the development of innovative and highly differentiated analgesic treatments for debilitating pain conditions with large unmet needs, placing a particular emphasis on addressing migraine, neuropathic and musculoskeletal pain, enabling doctors to provide safe, effective, and accessible pain relief solutions for the multitude of patients worldwide grappling with poorly managed pain conditions.
Contact Information
Website
www.brisepharma.comCorporate Office
- 2555 Xiupu Road
- Building E3, 8F
- Shanghai
- China
Corporate Office
- 2555 Xiupu Road
- Building E3, 8F
- Shanghai
- China
Brise Pharma Timeline
Brise Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC (Series B) | Cancelled | Clinical Trials - Phase 2 | ||||
| 4. Early Stage VC (Series A2) | 17-Nov-2025 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC | 31-Mar-2024 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC | 30-Jun-2023 | $15M | $35M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC | 31-Oct-2021 | $20M | $20M | Completed | Startup |
Brise Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Brise Pharma Patents
Brise Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-7510208-B2 | Anti-trka antibodies or antigen-binding fragments thereof, methods for preparation and uses thereof | Active | 28-Feb-2021 | ||
| JP-2023526413-A | Anti-trka antibody or antigen-binding fragment thereof, method of preparation and use thereof | Active | 28-Feb-2021 | ||
| JP-2023512313-A | Anti-ngf antibody and antigen-binding fragment thereof, preparation and use thereof | Pending | 06-Aug-2020 | C07K16/22 |
Brise Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Brise Pharma Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CBC Group (Singapore) | PE/Buyout | Minority | ||
| Guanghua Kaiyuan Capital | Asset Manager | Minority | ||
| INCE Capital | Venture Capital | Minority | ||
| Proxima Capital | Venture Capital | Minority | ||
| Beijing Shunxi Private Equity Fund Management | Growth/Expansion | Minority |
Brise Pharma FAQs
-
When was Brise Pharma founded?
Brise Pharma was founded in 2021.
-
Where is Brise Pharma headquartered?
Brise Pharma is headquartered in Shanghai, China.
-
What is the size of Brise Pharma?
Brise Pharma has 50 total employees.
-
What industry is Brise Pharma in?
Brise Pharma’s primary industry is Drug Discovery.
-
Is Brise Pharma a private or public company?
Brise Pharma is a Private company.
-
What is Brise Pharma’s current revenue?
The current revenue for Brise Pharma is .
-
How much funding has Brise Pharma raised over time?
Brise Pharma has raised $71.9M.
-
Who are Brise Pharma’s investors?
CBC Group (Singapore), Guanghua Kaiyuan Capital, INCE Capital, Proxima Capital, and Beijing Shunxi Private Equity Fund Management are 5 of 9 investors who have invested in Brise Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
